Abstract
Comparing Outcomes between Liposomal Daunorubicin/Cytarabine (CPX-351) and HMA+Venetoclax As Frontline Therapy in Acute Myeloid Leukemia
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have